1168 related articles for article (PubMed ID: 18396691)
21. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
Hehr T; Friedel G; Steger V; Spengler W; Eschmann SM; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1376-81. PubMed ID: 19864078
[TBL] [Abstract][Full Text] [Related]
22. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
25. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
[TBL] [Abstract][Full Text] [Related]
26. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
27. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
28. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
30. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
31. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.
Ratanatharathorn V; Lorvidhaya V; Kraipiboon P; Sirachainan E; Maoleekoonpairoj S; Phromratanapongse P; Cheirsilpa A; Tangkaratt S; Srimuninnimit V; Pattaranutaporn P; Lertsanguansinchai P
J Med Assoc Thai; 2000 Jan; 83(1):85-92. PubMed ID: 10710874
[TBL] [Abstract][Full Text] [Related]
33. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Aisner J; Belani CP; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin MJ
Semin Oncol; 1995 Oct; 22(5 Suppl 12):17-21. PubMed ID: 7481856
[TBL] [Abstract][Full Text] [Related]
34. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
DeVore RF; Jagasia M; Johnson DH
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
37. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
